Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001239259 | SCV001412117 | uncertain significance | T-cell immunodeficiency, congenital alopecia, and nail dystrophy | 2023-12-02 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 31 of the FOXN1 protein (p.Pro31Leu). This variant is present in population databases (rs771909592, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with FOXN1-related conditions. ClinVar contains an entry for this variant (Variation ID: 964931). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV001239259 | SCV004183549 | uncertain significance | T-cell immunodeficiency, congenital alopecia, and nail dystrophy | 2023-11-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004034605 | SCV004871598 | uncertain significance | Inborn genetic diseases | 2024-01-04 | criteria provided, single submitter | clinical testing | The c.92C>T (p.P31L) alteration is located in exon 1 (coding exon 1) of the FOXN1 gene. This alteration results from a C to T substitution at nucleotide position 92, causing the proline (P) at amino acid position 31 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |